Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The TAK1-TAB1 complex is a central mediator of inflammatory and stress signaling in mammalian cells. TAK1 (MAP3K7) is a serine/threonine kinase activated by cytokines and receptor ligands, leading to activation of NF-κB and MAPK pathways. TAB1 acts as an adapter that binds to TAK1, enhancing its kinase activity and facilitating downstream signaling. The complex is regulated by post-translational modifications, including phosphorylation and ubiquitination, and is essential for mediating cellular responses to proinflammatory stimuli, regulating cell death pathways, and modulating immune and stress responses in health and disease.
Kinase inhibition (drugs inhibit TAK1's kinase activity, blocking NF-κB and MAPKs activation); Disruption of protein–protein interaction (e.g., agents interfering with TAK1–TAB1 binding)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transforming growth factor-β-activated kinase 1–TAK1-binding protein 1 complex (TAK1-TAB1 complex).